Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Acrivon Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 44 | 46 | +2 |
| Shares | 16.2M | 21.4M | +5.17M (+31.8%) |
| Value | $22.6M | $38.1M | +$15.5M (+68.8%) |
New holders (6)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 41,276 | $73.5K | 0.00% |
| Spark Investment Management LLC | 28,300 | $50.4K | 0.10% |
| Verdad Advisers, LP | 15,054 | $26.8K | 0.03% |
| HRT Financial LP | 10,316 | $18.0K | 0.00% |
| Crews Bank & Trust | 1,044 | $1.86K | 0.00% |
| Citigroup Inc | 6 | $11 | 0.00% |
Sold out (4)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Panagora Asset Management Inc | 33,814 | $47.0K |
| Two Sigma Securities, LLC | 11,679 | $16.2K |
| Vanguard Global Advisers, LLC | 4,453 | $6.19K |
| Wells Fargo & Company | 3,000 | $4.17K |